StockNews.AI
NAMS
StockNews.AI
18 hrs

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

1. NewAmsterdam Pharma will participate in Stifel's Cardiometabolic Forum on September 30. 2. The company develops oral therapies for cardiovascular disease with unmet needs. 3. Obicetrapib is in phase 3 trials aimed at lowering LDL cholesterol levels. 4. Leadership's dialogue at the forum may provide strategic insights to investors. 5. The focus is on patients who poorly tolerate current CVD therapies.

4m saved
Insight
Article

FAQ

Why Bullish?

Increased visibility and engagement at the forum could attract investor interest, similar to how public disclosures about pipeline developments impacted other biopharmaceutical companies positively in the past.

How important is it?

The forum provides an opportunity for dialogue, which can enhance market perception and investor confidence.

Why Short Term?

The virtual event is imminent, offering immediate insights that may influence short-term trading actions.

Related Companies

AMGNREGNMRNA
September 24, 2025 08:00 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that John Kastelein, Chief Scientific Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on Tuesday, September 30, 2025 at 11:00 a.m. ET. A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: 1-917-882-7512matthew.philippe@newamsterdampharma.com Media ContactReal Chemistry on behalf of NewAmsterdamChristian EdgingtonP: 1-513-310-6410cedgington@realchemistry.com Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: 1-212-698-8696 austin.murtagh@precisionaq.com

Related News